Difference between revisions of "Team:IISER Kolkata/Description"

 
(31 intermediate revisions by 3 users not shown)
Line 8: Line 8:
 
<script src="https://2019.igem.org/wiki/index.php?title=Team:IISER_Kolkata/.js&action=raw&ctype=text/javascript" defer></script>
 
<script src="https://2019.igem.org/wiki/index.php?title=Team:IISER_Kolkata/.js&action=raw&ctype=text/javascript" defer></script>
 
<script src="https://2019.igem.org/wiki/index.php?title=Team:IISER_Kolkata/common.js&action=raw&ctype=text/javascript" defer></script>
 
<script src="https://2019.igem.org/wiki/index.php?title=Team:IISER_Kolkata/common.js&action=raw&ctype=text/javascript" defer></script>
 +
 +
<style>
 +
div#navigate {
 +
align-self: center;
 +
margin: 2vmax;
 +
position: relative;
 +
width: 70vw;
 +
height: 35vw;
 +
}
 +
#navigate img {
 +
width: 100%;
 +
height: 100%;
 +
}
 +
span.scroll_link {
 +
position: absolute;
 +
background-color: none;
 +
border-radius: 100%;
 +
width: 10vw;
 +
height: 10vw;
 +
cursor: pointer;
 +
}
 +
.scroll_link#scroll1 {
 +
top: 7vw;
 +
left: 15vw;
 +
}
 +
.scroll_link#scroll2 {
 +
top: 24vw;
 +
left: 20vw;
 +
}
 +
.scroll_link#scroll3 {
 +
top: 0vw;
 +
left: 29vw;
 +
}
 +
.scroll_link#scroll4 {
 +
top: 24vw;
 +
left: 41vw;
 +
}
 +
.scroll_link#scroll5 {
 +
top: 5vw;
 +
left: 43vw;
 +
}
 +
/*mobile mode*/
 +
@media screen and (orientation: portrait) {
 +
div#navigate {
 +
width: 100vw;
 +
height: 50vw;
 +
}
 +
#navigate img {
 +
width: 100%;
 +
height: 100%;
 +
}
 +
span.scroll_link {
 +
width: 15vw;
 +
height: 15vw;
 +
}
 +
.scroll_link#scroll1 {
 +
top: 8vw;
 +
left: 22vw;
 +
}
 +
.scroll_link#scroll2 {
 +
top: 33vw;
 +
left: 27vw;
 +
}
 +
.scroll_link#scroll3 {
 +
top: 0vw;
 +
left: 41vw;
 +
}
 +
.scroll_link#scroll4 {
 +
top: 33vw;
 +
left: 58vw;
 +
}
 +
.scroll_link#scroll5 {
 +
top: 6vw;
 +
left: 62vw;
 +
}
 +
}
 +
</style>
 +
 +
<script>
 +
$(window).on("load", function() {
 +
var navHeight = $("#navbar #mobdiv").height();
 +
var sec1Pos = $("#sec1").offset().top - navHeight;
 +
    var sec2Pos = $("#sec2").offset().top - navHeight;
 +
    var sec3Pos = $("#sec3").offset().top - navHeight;
 +
    var sec4Pos = $("#sec4").offset().top - navHeight;
 +
    var sec5Pos = $("#sec5").offset().top - navHeight;
 +
//scroll to section when navigation is clicked
 +
$(document).on("click", "#scroll1", function() {
 +
        $("body, html").animate({scrollTop: sec1Pos}, 1000, "swing");
 +
    });
 +
    $(document).on("click", "#scroll2", function() {
 +
        $("body, html").animate({scrollTop: sec2Pos}, 1000, "swing");
 +
    });
 +
    $(document).on("click", "#scroll3", function() {
 +
        $("body, html").animate({scrollTop: sec3Pos}, 1000, "swing");
 +
    });
 +
    $(document).on("click", "#scroll4", function() {
 +
        $("body, html").animate({scrollTop: sec4Pos}, 1000, "swing");
 +
    });
 +
    $(document).on("click", "#scroll5", function() {
 +
        $("body, html").animate({scrollTop: sec5Pos}, 1000, "swing");
 +
    });
 +
});
 +
</script>
 
 
 
<nav id="navbar">
 
<nav id="navbar">
Line 23: Line 127:
 
<ul class="dropdown">
 
<ul class="dropdown">
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Team">Members</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Team">Members</a></div></li>
 +
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Guides">Guides</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Collaborations">Collaborations</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Collaborations">Collaborations</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Attributions">Attributions</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Attributions">Attributions</a></div></li>
Line 35: Line 140:
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Contribution">Contribution</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Contribution">Contribution</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Results">Results</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Results">Results</a></div></li>
−
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Demonstrate">Demonstrate</a></div></li>
 
−
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Improve">Improve</a></div></li>
 
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Model">Model</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Model">Model</a></div></li>
 
</ul>
 
</ul>
Line 51: Line 154:
 
<li id="humanityMenu"><div><a href="">Humanity</a></div>
 
<li id="humanityMenu"><div><a href="">Humanity</a></div>
 
<ul class="dropdown">
 
<ul class="dropdown">
−
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Human_Practices">Practices</a></div></li>
+
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Practices_Overview">Overview</a></div></li>
 +
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Human_Practices">Integrated&nbsp;HP</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Public_Engagement">Engagement</a></div></li>
 
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Public_Engagement">Engagement</a></div></li>
 +
<li><div><a href="https://2019.igem.org/Team:IISER_Kolkata/Social_Studies">Social</a></div></li>
 
</ul>
 
</ul>
 
</li>
 
</li>
Line 59: Line 164:
 
              
 
              
 
                 <div id="container">
 
                 <div id="container">
−
                        <h1 class="heading">Description</h1>
+
<h1 class="heading">Description and Inspiration</h1>
 +
 
 +
<section class="sec white">
 +
<p style="text-align: center">
 +
    <em>“Unavailability of a vaccine and limited chemotherapeutic options coupled with the rapid emergence of drug-resistant <i>Leishmania</i> strains challenges researchers to come up with novel strategies to combat the disease”</em>
 +
</p>
 +
        <p style="text-align: right">-Subrata Adak and Rupak Datta [10]</p>
 +
<div id="navigate">
 +
<img src="https://static.igem.org/mediawiki/2019/7/7e/T--IISER_Kolkata--description.png"/>
 +
</figure>
 +
<span class="scroll_link" id="scroll1"></span>
 +
<span class="scroll_link" id="scroll2"></span>
 +
<span class="scroll_link" id="scroll3"></span>
 +
<span class="scroll_link" id="scroll4"></span>
 +
<span class="scroll_link" id="scroll5"></span>
 +
</div>
 +
</section>
 +
 
 +
<section id="sec1" class="sec white">
 +
<h3>
 +
    What is Leishmaniasis?
 +
</h3>
 +
<figure>
 +
<img class="bigimage" src="https://static.igem.org/mediawiki/2019/0/0a/T--IISER_Kolkata--sandfly_bite.png"/>
 +
<figcaption>Figure 1 - How different forms of <i>Leishmania</i> causes damage</figcaption>
 +
</figure>
 +
<p>
 +
    Leishmaniasis is caused by a <b>protozoan parasite</b> from over 20 <i>Leishmania</i>
 +
    species. <i>Leishmania</i> is able to persist in host cells by evading or
 +
    exploiting host immune mechanisms. The parasite lies exclusively
 +
    intracellularly, mainly inside macrophages as replicating amastigotes.
 +
    These amastigotes multiply and burst out of these macrophages and infect
 +
    other cells. There are 3 main forms of leishmaniasis – <b>visceral</b> (also known
 +
    as kala-azar and the most serious form of the disease), <b>cutaneous</b> (the most
 +
    common), and <b>mucocutaneous</b>. The following flow chart explains the process
 +
    through which the parasite wreaks havoc.
 +
</p>
 +
<figure>
 +
<img class="bigimage" src="https://static.igem.org/mediawiki/2019/f/f6/T--IISER_Kolkata--flowchart.png"/>
 +
<figcaption>Figure 2 - Lifecycle of the parasite in the human body</figcaption>
 +
</figure>
 +
</section>
 +
 
 +
<section id="sec2" class="sec white">
 +
<h3>
 +
    The Problem
 +
</h3>
 +
<figure>
 +
<img class="bigimage" src="https://static.igem.org/mediawiki/2019/8/8d/T--IISER_Kolkata--world_problem.png"/>
 +
<figcaption>Figure 3 ( Source [2] )</figcaption>
 +
</figure>
 +
<p>
 +
    It is the world's second most deadly parasitic disease after malaria, in terms of mortality [1]. The World Health Organization data indicates that an estimated 700,000 to 1 million new cases and 20,000 to 30,000 deaths by leishmaniasis occur annually in the world.
 +
</p>
 +
<p>
 +
    Categorized as a <b>Neglected Tropical Disease</b> - a diverse group of communicable diseases that prevail in tropical and subtropical conditions in more than 149 countries, and are relatively overlooked by developed nations. These affect more than one billion people and cost developing economies billions of dollars every year.
 +
</p>
 +
<p>
 +
    The disease devastates some of the poorest people on earth and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources. It is also linked to environmental changes such as deforestation, the building of dams, irrigation schemes, and urbanization etc [2].
 +
</p>
 +
<p>
 +
    Different forms of leishmaniasis and its spread across the world:
 +
</p>
 +
    <table class="tabular">
 +
  <caption>Table 1</caption>
 +
  <tr>
 +
    <th>Type</th>
 +
    <th>Countries affected</th>
 +
    <th>Severity</th>
 +
  </tr>
 +
  <tr>
 +
    <td>Visceral leishmaniasis</td>
 +
    <td>Brazil, Ethiopia, India, Kenya, Somalia, South Sudan and Sudan</td>
 +
    <td>50,000 to 90,000 new cases</td>
 +
  </tr>
 +
  <tr>
 +
    <td>Cutaneous leishmaniasis</td>
 +
    <td>Afghanistan, Algeria, Brazil, Colombia, Iran and the Syrian Arab Republic</td>
 +
    <td>600,000 to 1 million new cases</td>
 +
  </tr>
 +
  <tr>
 +
    <td>Mucocutaneous leishmaniasis</td>
 +
    <td>Bolivia, Brazil, Ethiopia and Peru</td>
 +
    <td>90% of mucocutaneous leishmaniasis cases</td>
 +
  </tr>
 +
</table>
 +
<p>
 +
    India, Nepal, and Bangladesh have more than 50% of the global burden of
 +
    visceral leishmaniasis. In 2005, these countries committed to eliminate visceral
 +
    leishmaniasis as a public health problem, but another outbreak occurred in 2005. The projected deadline for this eradication was 2015, but this deadline is far from being met.
 +
</p>
 +
</section>
 +
 
 +
<section id="sec3" class="sec white">
 +
<h3>
 +
    A Local Perspective: Visceral Leishmaniasis (VL) in India
 +
</h3>
 +
<p>
 +
    Ever since its first documentation by military surgeon William Twining in
 +
    the 19th century, visceral leishmaniasis (locally known as kala-azar) has
 +
    been a problem in India [3]. At present, it is a serious public health
 +
    problem in Indian subcontinent. In India, kala-azar is endemic in Bihar,
 +
    Jharkhand, <b>West Bengal</b> (Our state) , and Uttar Pradesh, making it an issue which is also
 +
    of greater relevance to the community here at IISER Kolkata because we are
 +
    at the epicentre of this problem.
 +
</p>
 +
<figure>
 +
<img class="bigimage" src="https://static.igem.org/mediawiki/2019/1/1d/T--IISER_Kolkata--India_incidence.png"/>
 +
<figcaption>Figure 4 ( Source [2] )</figcaption>
 +
</figure>
 +
</section>
 +
 
 +
<section id="sec4" class="sec white">
 +
<h3>
 +
    Why tackle a solved problem?
 +
</h3>
 +
<p>
 +
    From the outlook, the eradication programs look like a success on paper, but
 +
    from our extensive literature survey, iGEM IISER-Kolkata team found out that
 +
    there are some concerning information that could be detrimental to the
 +
    eradication program.
 +
</p>
 +
<ul>
 +
    <li>
 +
            <strong>Epidemiological pattern:</strong>
 +
        </li>
 +
</ul>
 +
<p>
 +
    Even though the programme appeared to have contributed to a global decline of VL, but
 +
    significantly, the disease commonly shows a cyclical epidemiological
 +
    pattern, as depicted in the figure below. The parasite is known to be
 +
    drug-resistant (antimonial drugs are not effective in many areas of India
 +
                                    due to over-use) and hence we may in a position where a resurgence of
 +
                                    kala-azar can occur
 +
    [3]
 +
</p>
 +
<figure>
 +
<img class="bigimage" src="https://static.igem.org/mediawiki/2019/a/af/T--IISER_Kolkata--number_cases.png"/>
 +
<figcaption>Figure 5 - Kala-azar cases in India during the period from 1987 to 2011 (source: Directorate General of Health Services, National Vector Borne Disease Control Programme (NVBDCP), Government of India, and State Health Society, Bihar, India). ( Source [12] )</figcaption>
 +
</figure>
 +
<ul>
 +
    <li>
 +
            <strong>Deadly Treatment:</strong>
 +
        </li>
 +
</ul>
 +
<p>
 +
    There is no vaccine available for VL; hence control of VL exclusively
 +
    depends on chemotherapy. Liposomal Amphotericin B, Paromomycin and
 +
    Miltefosine are currently widely used for this purpose. But these
 +
    treatments have toxic side-effects (shown in the table below) that
 +
    ironically required other treatments and sometimes
 +
    hospitalisation [4].
 +
</p>
 +
<table class="tabular">
 +
  <caption>Table 2</caption>
 +
  <tr>
 +
    <th>Medicines </th>
 +
    <th>Side Effects</th>
 +
  </tr>
 +
  <tr>
 +
    <td>Liposomal Amphotericin B</td>
 +
    <td>Infusion related fever and rigor<br/>Chills<br/>Vomiting<br/>Backache</td>
 +
  </tr>
 +
  <tr>
 +
    <td>Paromomycin</td>
 +
    <td>Ototoxicity<br/>Nephrotoxicity</td>
 +
  </tr>
 +
  <tr>
 +
    <td>Miltefosine</td>
 +
    <td>Gastrointestinal effects (vomiting, diarrhea, abdominal pain) (major)<br/> Nephrotoxicity (decreased urine, renal failure) (major)<br/> Hepatotoxicity (jaundice) (major)<br/> Any other, unanticipated (edema, anemia)</td>
 +
  </tr>
 +
  <tr>
 +
    <td>Amphotericin B</td>
 +
    <td>Fever with chills and rigors (major)<br/> Vomiting, dehydration (major)<br/> Edema, decreased urine, renal failure<br/> Arrhythmias (major)</td>
 +
  </tr>
 +
</table>
 +
<ul>
 +
    <li>
 +
            <strong>And costly too!</strong>
 +
        </li>
 +
</ul>
 +
<p>
 +
    The cost of treatment is important when patients need to pay for treatment
 +
    as ~75 % of the VL cases in Bihar live below the poverty threshold of less
 +
    than US $ 1.0 a day, and this is similar in other endemic countries
 +
    although exact data are scarce [5]. Poverty seriously affects the prognosis
 +
    of VL because most of the patients and their families have to pay for
 +
    diagnosis, drugs and hospital care, and this is often half or more of the
 +
    annual household income [6]. As a result, families with a VL infected
 +
    member descend deeper into poverty [7].
 +
</p>
 +
<ul>
 +
    <li>
 +
            <strong>Post Kala-azar Dermal Leishmaniasis (PKDL):</strong>
 +
        </li>
 +
</ul>
 +
<p>
 +
    Post kala-azar dermal leishmaniasis is a complication of VL. it is
 +
    characterised by a macular, maculopapular, and nodular rash in a patient
 +
    who has recovered from VL and who is otherwise well [8]. PKDL probably has
 +
    an important role in interepidemic periods of VL, acting as a reservoir for
 +
    parasites. The alarming fact is that PKDL can occur in VL cured patients
 +
    within a period of few months to many years!
 +
</p>
 +
<p>
 +
    The eradication program fails to keep the number of cases of PKDL down.
 +
    While then number of VL cases are decreasing every year, the number of PKDL
 +
    cases is increasing. <b>From only 499 cases in 2013, it jumped to 1982 cases
 +
    in 2017</b> and there seems to be no stopping [9].
 +
</p>
 +
</section>
 +
 
 +
<section id="sec5" class="sec white">
 +
<h3>
 +
    Our Solution:  <b>UnLeish</b>
 +
</h3>
 +
                                <figure>
 +
<img class="bigimage" src="https://static.igem.org/mediawiki/2019/f/f3/T--IISER_Kolkata--solution.png"/>
 +
<figcaption>Figure 6 - Method of elimination</figcaption>
 +
</figure>
 +
<p>
 +
    We plan to do this by genetically engineering a bacterium which can sense a
 +
    <i>Leishmania major</i>-infected macrophage using a Nitric Oxide (NO) sensor. In
 +
    response, it will express an iron chelator (Aerobactin) to efficiently kill
 +
    the <i>Leishmania</i> parasites.
 +
</p>
 +
<p>
 +
    <strong>Why Nitric Oxide?</strong>
 +
</p>
 +
<p>
 +
    Nitric Oxide (NO) is an intracellular secondary messenger which regulates
 +
    various physiological functions. The generation of reactive oxygen and
 +
    reactive nitrogen species, in response to pathogen attacks, play a central
 +
    role in host (macrophage) defence mechanism. The <i>Leishmania</i> parasite
 +
    cleverly evades the assault by evolving several defence strategies. We
 +
    exploited one of these mechanisms to detect a <i>Leishmania</i>-infected
 +
    macrophage [10].
 +
</p>
 +
<p>
 +
    Whenever a pathogen is phagocytosed into a macrophage, nitric oxide
 +
    levels inside that macrophage rise drastically up (C2) as an immunological
 +
    response from basal levels (C1). But, the parasite has the ability to
 +
    down-regulates this increase and brings it to a lower level because NO is
 +
    not only a reactive oxygen species, but also it plays a major role in
 +
    activating other immunological response that is detrimental for survival of
 +
    the parasite.
 +
</p>
 +
<p>
 +
    Our bio-sensor detects this downregulation of NO and in the process senses
 +
    the parasite-infected macrophage.
 +
</p>
 +
<p>
 +
    <strong>Elimination by Chelation:</strong>
 +
</p>
 +
<p>
 +
    Iron is a vital nutritional requirement for virtually all organisms,
 +
    including pathogenic trypanosomatid parasites (<i>Leishmania</i>), and plays a
 +
    crucial role in many facets of cellular metabolism as a cofactor of several
 +
    enzymes. Iron acquisition is essential for the survival of parasites. In
 +
    the macrophage, <i>Leishmania</i> tampers with the iron regulation system and
 +
    increases the intake of iron so that it can utilise a part of it for its
 +
    survival [11].
 +
</p>
 +
<p>
 +
    After our biosensor detects a parasite-infected macrophage, our proposed
 +
    GMO plans to chelate all Iron inside the macrophage by producing an Iron
 +
    chelator. This will severely hamper the growth and reproduction of the
 +
    parasite and subsequently eliminate it.
 +
</p>
 +
<figure>
 +
<img class="fullimage" src="https://static.igem.org/mediawiki/2019/2/27/T--IISER_Kolkata--NO_aerobactin.png"/>
 +
<figcaption>Figure 7 - Diagram illustrating our GMO in action. It <u>only</u> produces Aerobactin when it senses the parasite infected macrophage</figcaption>
 +
</figure>
 +
</section>
  
 
<section class="sec white">
 
<section class="sec white">
−
<h3>Why Leishmaniasis?</h3>
+
<h3>
−
<p>Kala-azar or leishmaniasis is a deadly parasitic disease caused by <i>Leishmania</i> parasites. All of the world including the Indian subcontinent has been working arduously to eradicate this disease.</p>
+
    References
−
<p>But despite multiple campaigns, even though the number of cases has reduced drastically, a large number of cases still occur. These cases are becoming increasingly alarming since drug therapy is proving less and less effective in their treatment. To make matters worse, Post Kala-azar Dermal Leishmaniasis, PKDL is also a rising risk, due to the increasing number of cases and the steady reservoir of Leishmania parasites that is always present in our subcontinent.</p>
+
</h3>
−
<p>Due to the unavailability of vaccination and failing drug treatment due to rising resistance, a path is being paved for an epidemic. This is what we aim to circumvent by completely removing the <i>Leishmania</i> reservoir from the country by our diagnosis and treatment strategy.</p>
+
<ol>
 +
    <li>
 +
            <a href="https://www.ncbi.nlm.nih.gov/pubmed/29317800" target="_blank">Ghorbani, M., & Farhoudi, R. (2017). Leishmaniasis in humans: drug or vaccine therapy?. Drug design, development and therapy, 12, 25–40. doi:10.2147/DDDT.S146521</a>
 +
        </li>
 +
    <li>
 +
            <a href="https://www.who.int/news-room/fact-sheets/detail/leishmaniasis" target="_blank">Leishmaniasis. (n.d.). Retrieved from https://www.who.int/news-room/fact-sheets/detail/leishmaniasis.</a>
 +
        </li>
 +
    <li>
 +
            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312593/" target="_blank">Steverding D. (2017). The history of leishmaniasis. Parasites & vectors, 10(1), 82. doi:10.1186/s13071-017-2028-5</a>
 +
        </li>
 +
    <li>
 +
            <a href="https://www.cambridge.org/core/journals/parasitology/article/chemotherapy-of-leishmaniasis-present-challenges/35007DCCC08E3A791BD39F112FE52831" target="_blank">
 +
ULIANA, S., TRINCONI, C., & COELHO, A. (2018). Chemotherapy of leishmaniasis: Present challenges. Parasitology, 145(4), 464-480. doi:10.1017/S0031182016002523
 +
</a>
 +
        </li>
 +
    <li>
 +
            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782357/#CR6" target="_blank">Boelaert, M. , Meheus, F. , Sanchez, A. , Singh, S. P., Vanlerberghe, V. , Picado, A. , Meessen, B. and Sundar, S. (2009), The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Tropical Medicine & International Health, 14: 639-644. </a>
 +
        </li>
 +
    <li>
 +
            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782357/#CR7" target="_blank">Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, et al. (2010) Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. PLOS Neglected Tropical Diseases 4(9): e818. doi.org/10.1371/journal.pntd.0000818</a>
 +
        </li>
 +
    <li>
 +
            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782357/" target="_blank">Singh, O. P., Singh, B., Chakravarty, J., & Sundar, S. (2016). Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infectious diseases of poverty, 5, 19. doi:10.1186/s40249-016-0112-2</a>
 +
        </li>
 +
    <li>
 +
            <a href="https://www.ncbi.nlm.nih.gov/pubmed/12560194" target="_blank">Zijlstra, E. E., Musa, A. M., Khalil, E. A. G., el-Hassan, I. M., & el-Hassan, A. M. (2003, February). Post-kala-azar dermal leishmaniasis. </a>
 +
        </li>
 +
    <li>
 +
            <a href="https://nvbdcp.gov.in/index4.php?lang=1&amp;level=0&amp;linkid=467&amp;lid=3750" target="_blank">Ministry of Health & Family. (n.d.). KALA-AZAR SITUATION IN INDIA. </a>
 +
        </li>
 +
    <li>
 +
            Adak, Subrata, and Rupak Datta. <i>Leishmania</i> Current Biology and Control. Caister Academic Press, 2015.
 +
        </li>
 +
    <li>
 +
    <a href="https://www.sciencedirect.com/science/article/pii/S0166685116301670" target="_blank">Zaidi, A., Singh, K. P., & Ali, V. (2017). <i>Leishmania</i> and its quest for iron: An update and overview. Molecular and Biochemical Parasitology, 211, 15–25. doi: 10.1016/j.molbiopara.2016.12.004</a>
 +
        </li>
 +
                                  <li>
 +
    <a href="https://www.hindawi.com/journals/isrn/2013/675846/" target="_blank">Bhunia, G. S., Kesari, S., Chatterjee, N., Kumar, V., & Das, P. (2013). The Burden of Visceral Leishmaniasis in India: Challenges in Using Remote Sensing and GIS to Understand and Control. ISRN Infectious Diseases, 2013, 1–14. doi: 10.5402/2013/675846</a>
 +
        </li>
 +
</ol>
 
</section>
 
</section>
 
                 </div>
 
                 </div>

Latest revision as of 02:17, 22 October 2019

Description and Inspiration

“Unavailability of a vaccine and limited chemotherapeutic options coupled with the rapid emergence of drug-resistant Leishmania strains challenges researchers to come up with novel strategies to combat the disease”

-Subrata Adak and Rupak Datta [10]

What is Leishmaniasis?

Figure 1 - How different forms of Leishmania causes damage

Leishmaniasis is caused by a protozoan parasite from over 20 Leishmania species. Leishmania is able to persist in host cells by evading or exploiting host immune mechanisms. The parasite lies exclusively intracellularly, mainly inside macrophages as replicating amastigotes. These amastigotes multiply and burst out of these macrophages and infect other cells. There are 3 main forms of leishmaniasis – visceral (also known as kala-azar and the most serious form of the disease), cutaneous (the most common), and mucocutaneous. The following flow chart explains the process through which the parasite wreaks havoc.

Figure 2 - Lifecycle of the parasite in the human body

The Problem

Figure 3 ( Source [2] )

It is the world's second most deadly parasitic disease after malaria, in terms of mortality [1]. The World Health Organization data indicates that an estimated 700,000 to 1 million new cases and 20,000 to 30,000 deaths by leishmaniasis occur annually in the world.

Categorized as a Neglected Tropical Disease - a diverse group of communicable diseases that prevail in tropical and subtropical conditions in more than 149 countries, and are relatively overlooked by developed nations. These affect more than one billion people and cost developing economies billions of dollars every year.

The disease devastates some of the poorest people on earth and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources. It is also linked to environmental changes such as deforestation, the building of dams, irrigation schemes, and urbanization etc [2].

Different forms of leishmaniasis and its spread across the world:

Table 1
Type Countries affected Severity
Visceral leishmaniasis Brazil, Ethiopia, India, Kenya, Somalia, South Sudan and Sudan 50,000 to 90,000 new cases
Cutaneous leishmaniasis Afghanistan, Algeria, Brazil, Colombia, Iran and the Syrian Arab Republic 600,000 to 1 million new cases
Mucocutaneous leishmaniasis Bolivia, Brazil, Ethiopia and Peru 90% of mucocutaneous leishmaniasis cases

India, Nepal, and Bangladesh have more than 50% of the global burden of visceral leishmaniasis. In 2005, these countries committed to eliminate visceral leishmaniasis as a public health problem, but another outbreak occurred in 2005. The projected deadline for this eradication was 2015, but this deadline is far from being met.

A Local Perspective: Visceral Leishmaniasis (VL) in India

Ever since its first documentation by military surgeon William Twining in the 19th century, visceral leishmaniasis (locally known as kala-azar) has been a problem in India [3]. At present, it is a serious public health problem in Indian subcontinent. In India, kala-azar is endemic in Bihar, Jharkhand, West Bengal (Our state) , and Uttar Pradesh, making it an issue which is also of greater relevance to the community here at IISER Kolkata because we are at the epicentre of this problem.

Figure 4 ( Source [2] )

Why tackle a solved problem?

From the outlook, the eradication programs look like a success on paper, but from our extensive literature survey, iGEM IISER-Kolkata team found out that there are some concerning information that could be detrimental to the eradication program.

  • Epidemiological pattern:

Even though the programme appeared to have contributed to a global decline of VL, but significantly, the disease commonly shows a cyclical epidemiological pattern, as depicted in the figure below. The parasite is known to be drug-resistant (antimonial drugs are not effective in many areas of India due to over-use) and hence we may in a position where a resurgence of kala-azar can occur [3]

Figure 5 - Kala-azar cases in India during the period from 1987 to 2011 (source: Directorate General of Health Services, National Vector Borne Disease Control Programme (NVBDCP), Government of India, and State Health Society, Bihar, India). ( Source [12] )
  • Deadly Treatment:

There is no vaccine available for VL; hence control of VL exclusively depends on chemotherapy. Liposomal Amphotericin B, Paromomycin and Miltefosine are currently widely used for this purpose. But these treatments have toxic side-effects (shown in the table below) that ironically required other treatments and sometimes hospitalisation [4].

Table 2
Medicines Side Effects
Liposomal Amphotericin B Infusion related fever and rigor
Chills
Vomiting
Backache
Paromomycin Ototoxicity
Nephrotoxicity
Miltefosine Gastrointestinal effects (vomiting, diarrhea, abdominal pain) (major)
Nephrotoxicity (decreased urine, renal failure) (major)
Hepatotoxicity (jaundice) (major)
Any other, unanticipated (edema, anemia)
Amphotericin B Fever with chills and rigors (major)
Vomiting, dehydration (major)
Edema, decreased urine, renal failure
Arrhythmias (major)
  • And costly too!

The cost of treatment is important when patients need to pay for treatment as ~75 % of the VL cases in Bihar live below the poverty threshold of less than US $ 1.0 a day, and this is similar in other endemic countries although exact data are scarce [5]. Poverty seriously affects the prognosis of VL because most of the patients and their families have to pay for diagnosis, drugs and hospital care, and this is often half or more of the annual household income [6]. As a result, families with a VL infected member descend deeper into poverty [7].

  • Post Kala-azar Dermal Leishmaniasis (PKDL):

Post kala-azar dermal leishmaniasis is a complication of VL. it is characterised by a macular, maculopapular, and nodular rash in a patient who has recovered from VL and who is otherwise well [8]. PKDL probably has an important role in interepidemic periods of VL, acting as a reservoir for parasites. The alarming fact is that PKDL can occur in VL cured patients within a period of few months to many years!

The eradication program fails to keep the number of cases of PKDL down. While then number of VL cases are decreasing every year, the number of PKDL cases is increasing. From only 499 cases in 2013, it jumped to 1982 cases in 2017 and there seems to be no stopping [9].

Our Solution: UnLeish

Figure 6 - Method of elimination

We plan to do this by genetically engineering a bacterium which can sense a Leishmania major-infected macrophage using a Nitric Oxide (NO) sensor. In response, it will express an iron chelator (Aerobactin) to efficiently kill the Leishmania parasites.

Why Nitric Oxide?

Nitric Oxide (NO) is an intracellular secondary messenger which regulates various physiological functions. The generation of reactive oxygen and reactive nitrogen species, in response to pathogen attacks, play a central role in host (macrophage) defence mechanism. The Leishmania parasite cleverly evades the assault by evolving several defence strategies. We exploited one of these mechanisms to detect a Leishmania-infected macrophage [10].

Whenever a pathogen is phagocytosed into a macrophage, nitric oxide levels inside that macrophage rise drastically up (C2) as an immunological response from basal levels (C1). But, the parasite has the ability to down-regulates this increase and brings it to a lower level because NO is not only a reactive oxygen species, but also it plays a major role in activating other immunological response that is detrimental for survival of the parasite.

Our bio-sensor detects this downregulation of NO and in the process senses the parasite-infected macrophage.

Elimination by Chelation:

Iron is a vital nutritional requirement for virtually all organisms, including pathogenic trypanosomatid parasites (Leishmania), and plays a crucial role in many facets of cellular metabolism as a cofactor of several enzymes. Iron acquisition is essential for the survival of parasites. In the macrophage, Leishmania tampers with the iron regulation system and increases the intake of iron so that it can utilise a part of it for its survival [11].

After our biosensor detects a parasite-infected macrophage, our proposed GMO plans to chelate all Iron inside the macrophage by producing an Iron chelator. This will severely hamper the growth and reproduction of the parasite and subsequently eliminate it.

Figure 7 - Diagram illustrating our GMO in action. It only produces Aerobactin when it senses the parasite infected macrophage

References

  1. Ghorbani, M., & Farhoudi, R. (2017). Leishmaniasis in humans: drug or vaccine therapy?. Drug design, development and therapy, 12, 25–40. doi:10.2147/DDDT.S146521
  2. Leishmaniasis. (n.d.). Retrieved from https://www.who.int/news-room/fact-sheets/detail/leishmaniasis.
  3. Steverding D. (2017). The history of leishmaniasis. Parasites & vectors, 10(1), 82. doi:10.1186/s13071-017-2028-5
  4. ULIANA, S., TRINCONI, C., & COELHO, A. (2018). Chemotherapy of leishmaniasis: Present challenges. Parasitology, 145(4), 464-480. doi:10.1017/S0031182016002523
  5. Boelaert, M. , Meheus, F. , Sanchez, A. , Singh, S. P., Vanlerberghe, V. , Picado, A. , Meessen, B. and Sundar, S. (2009), The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Tropical Medicine & International Health, 14: 639-644.
  6. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, et al. (2010) Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. PLOS Neglected Tropical Diseases 4(9): e818. doi.org/10.1371/journal.pntd.0000818
  7. Singh, O. P., Singh, B., Chakravarty, J., & Sundar, S. (2016). Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infectious diseases of poverty, 5, 19. doi:10.1186/s40249-016-0112-2
  8. Zijlstra, E. E., Musa, A. M., Khalil, E. A. G., el-Hassan, I. M., & el-Hassan, A. M. (2003, February). Post-kala-azar dermal leishmaniasis.
  9. Ministry of Health & Family. (n.d.). KALA-AZAR SITUATION IN INDIA.
  10. Adak, Subrata, and Rupak Datta. Leishmania Current Biology and Control. Caister Academic Press, 2015.
  11. Zaidi, A., Singh, K. P., & Ali, V. (2017). Leishmania and its quest for iron: An update and overview. Molecular and Biochemical Parasitology, 211, 15–25. doi: 10.1016/j.molbiopara.2016.12.004
  12. Bhunia, G. S., Kesari, S., Chatterjee, N., Kumar, V., & Das, P. (2013). The Burden of Visceral Leishmaniasis in India: Challenges in Using Remote Sensing and GIS to Understand and Control. ISRN Infectious Diseases, 2013, 1–14. doi: 10.5402/2013/675846